Compare Danaher Corporation (DHR) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs NetEase Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while NetEase Inc trades at $124.24 (market cap $76.09B). The key difference: Danaher Corporation is far larger — about 2× NetEase Inc's market cap, and NetEase Inc pays the higher dividend (2.45%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and NetEase Inc for 73 Days on average.
| DHR | NTES | |
|---|---|---|
Market Cap | $152.87B | $76.09B |
Volume | 5,228,698 | 486,447 |
Sector | Health | Technology |
52-Week High | $242.05 | $152.85 |
52-Week Low | $161.91 | $109.26 |
Typical Hold Time | 69 Days | 73 Days |
Enterprise Value | $175.08B | $51.81B |
Dividend Yield | 0.74% | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
NetEase (NTES) trades at $119.60, down 0.84% with neutral technical signals. The company maintains strong fundamentals with $112.63B revenue and 27.88% net margin in 2025, though recent quarterly earnings show mixed results with two misses and one beat. Analyst consensus remains strongly bullish with 82% buy ratings and $168 price target, representing 40% upside potential from current levels.
NTES presents compelling value with reasonable P/E of 15.9 and strong cash flow generation, but faces execution risks from inconsistent earnings performance and competitive pressures in gaming. The stock's current valuation discount to analyst targets offers opportunity, though investors should monitor Q3 2026 results for sustained growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
